8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
May 5, 2026·SEC
Avalo Therapeutics, Inc.(AVTX)Earnings, Financials & Key Ratios
AVTX•NASDAQ
Price updated Jun 19, 2026
AboutAvalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.Show more
- Revenue$59K-86.6%
- EBITDA-$73M-6.2%
- Net Income-$78M-122.8%
- EPS (Diluted)-5.84-79.1%
- Gross Margin100%-45.4%
- EBITDA Margin-123018.64%-693.8%
- Operating Margin-123601.69%-695.6%
- Net Margin-132642.37%-1565.2%
- ROE-72.43%-44.7%
AVTX Key Insights
Avalo Therapeutics, Inc. (AVTX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Negative free cash flow
- ✗Sales declining 61.2% over 5 years
- ✗Shares diluted 24.3% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when AVTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AVTX Price & Volume
Avalo Therapeutics, Inc. (AVTX) stock price & volume — 10-year historical chart
Loading chart...
AVTX Growth Metrics
Avalo Therapeutics, Inc. (AVTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-61.19%
3 Years-85.16%
TTM-86.62%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-216.06%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-124.06%
Return on Capital
10 Years-98.42%
5 Years-126.4%
3 Years-114.18%
Last Year-58.98%
AVTX Recent Earnings
Avalo Therapeutics, Inc. (AVTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (18%)●Beat Revenue 2/12 qtrs (100%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.98+2.0%
$1.00
Rev
—
—
Q2 2026
Mar 23, 2026Metric
Actual
Est
EPS
$0.37+76.0%
$1.54
Rev
$79,500+34.7%
$59,000
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$2.19-31.1%
$1.67
Rev
—
—
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$1.92-34.3%
$1.43
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.98vs $1.00+2.0% | — |
| Q2 2026 | Mar 23, 2026 | $0.37vs $1.54+76.0% | $79,500vs $59,000+34.7% |
| Q4 2025 | Nov 6, 2025 | $2.19vs $1.67-31.1% | — |
| Q3 2025 | Aug 7, 2025 | $1.92vs $1.43-34.3% | — |
Based on last 12 quarters of dataView full earnings history →
AVTX Peer Comparison
Avalo Therapeutics, Inc. (AVTX) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 ARQT | 3.28B | 26.21 | -201.62 | 91.34% | -0.57% | -1.41% | 0.03 | |
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 TARS | 2.72B | 63.16 | -39.72 | 146.71% | -9.02% | -14.19% | 0.27 | |
 NUVL | 9.08B | 123.43 | -21.10 | -42.78% | ||||
 RCKT | 365.8M | 3.35 | -1.67 | -70.79% | 0.09 | |||
 ALDX | 118.23M | 1.96 | -3.50 | -0% | 0.35 |
Compare AVTX vs Peers
Avalo Therapeutics, Inc. (AVTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AVTX Income Statement
Avalo Therapeutics, Inc. (AVTX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 27.81M | 18.33M | 6.75M | 6.7M | 5.4M | 18.05M | 1.92M | 441K | 59K | 59K |
Revenue Growth % | 2312.24% | -34.11% | -63.17% | -0.76% | -19.42% | 234.4% | -89.34% | -77.08% | -86.62% | -86.62% |
Cost of Goods Sold | 635.65K | 7.48M | -566.52K | 300K | 1.49M | 3.43M | 1.28M | -366K | 0 | 17K |
COGS % of Revenue | 2.29% | 40.81% | -8.39% | 4.48% | 27.62% | 19.02% | 66.74% | -82.99% | - | - |
Gross Profit | 27.18M▲ 0% | 10.85M▼ 60.1% | 7.32M▼ 32.6% | 6.4M▼ 12.5% | 3.91M▼ 38.9% | 14.62M▲ 274.1% | 640K▼ 95.6% | 807K▲ 26.1% | 59K▼ 92.7% | 42K▲ 0% |
Gross Margin % | 97.71% | 59.19% | 108.39% | 95.52% | 72.38% | 80.98% | 33.26% | 182.99% | 100% | 71.19% |
Gross Profit Growth % | 483.54% | -60.08% | -32.55% | -12.54% | -38.94% | 274.12% | -95.62% | 26.09% | -92.69% | - |
Operating Expenses | 13.29M | 29.52M | 23.45M | 6.4M | 86.04M | 52.06M | 27.99M | 69.32M | 72.98M | 79.2M |
OpEx % of Revenue | 47.77% | 161.07% | 347.45% | 95.52% | 1593.94% | 288.39% | 1454.83% | 15718.59% | 123701.69% | - |
Selling, General & Admin | 8.91M | 19.2M | 11.61M | 19.76M | 24.66M | 20.71M | 10.3M | 17.24M | 22.9M | 24.19M |
SG&A % of Revenue | 32.05% | 104.76% | 171.95% | 294.95% | 456.8% | 114.74% | 535.34% | 3909.52% | 38813.56% | - |
Research & Development | 4.37M | 5.79M | 11.76M | 32.19M | 59.84M | 31.31M | 13.78M | 52.08M | 50.08M | 55.01M |
R&D % of Revenue | 15.72% | 31.57% | 174.27% | 480.56% | 1108.47% | 173.44% | 716.42% | 11809.07% | 84888.14% | - |
Other Operating Expenses | 0 | 13.66K | 83.11K | -45.55M | 1.55M | 38K | 3.91M | 0 | 0 | 0 |
Operating Income | 13.89M▲ 0% | -39.31M▼ 383.0% | -16.14M▲ 59.0% | 0▲ 100.0% | -82.13M▲ 0% | -37.44M▲ 54.4% | -27.35M▲ 26.9% | -68.51M▼ 150.5% | -72.92M▼ 6.4% | -79.16M▲ 0% |
Operating Margin % | 49.94% | -214.52% | -239.06% | - | -1521.56% | -207.41% | -1421.57% | -15535.6% | -123601.69% | -134164.41% |
Operating Income Growth % | 186.38% | -383.04% | 58.95% | 100% | - | 54.42% | 26.95% | -150.49% | -6.44% | - |
EBITDA | 14.32M | -37.46M | -12.25M | -45.45M | -80.48M | -37.27M | -27.19M | -68.34M | -72.58M | -78.93M |
EBITDA Margin % | 51.47% | -204.41% | -181.53% | -678.47% | -1490.87% | -206.49% | -1413.36% | -15497.28% | -123018.64% | -133781.36% |
EBITDA Growth % | 189.18% | -361.69% | 67.29% | -270.91% | -77.06% | 53.68% | 27.05% | -151.33% | -6.2% | -57.4% |
D&A (Non-Cash Add-back) | 425.48K | 1.85M | 3.88M | 1.84M | 1.66M | 166K | 158K | 169K | 344K | 226K |
EBIT | 13.89M | -14.9M | -17.39M | -47.29M | -82.13M | -37.44M | -23.44M | -68.51M | -72.92M | -90.57M |
Net Interest Income | -24.02K | 16.26K | 121.33K | 49K | -2.39M | -4.17M | -3.42M | 3.32M | 0 | 3.02M |
Interest Income | 0 | 16.26K | 121.33K | 49K | 0 | 0 | 0 | 3.32M | 0 | 3.02M |
Interest Expense | 24.02K | 0 | 0 | 0 | 2.39M | 4.17M | 3.42M | 0 | 0 | 0 |
Other Income/Expense | -53.64K | 54.93K | 147.29K | -67.18M | -2.41M | -4.19M | -4.18M | 33.5M | -5.17M | -5.41M |
Pretax Income | 13.84M▲ 0% | -40.09M▼ 389.7% | -15.99M▲ 60.1% | -67.18M▼ 320.1% | -84.55M▼ 25.9% | -41.63M▲ 50.8% | -31.53M▲ 24.3% | -35.02M▼ 11.1% | -78.09M▼ 123.0% | -84.57M▲ 0% |
Pretax Margin % | 49.75% | -218.73% | -236.88% | -1002.79% | -1566.23% | -230.62% | -1638.77% | -7939.91% | -132362.71% | -143340.68% |
Income Tax | 1.97M | -33.91K | 280.32K | -2.79M | -196K | 28K | 14K | 114K | 165K | 169K |
Effective Tax Rate % | 14.21% | 0.08% | -1.75% | 4.16% | 0.23% | -0.07% | -0.04% | -0.33% | -0.21% | -0.2% |
Net Income | 11.87M▲ 0% | -40.05M▼ 437.4% | -16.07M▲ 59.9% | -63.5M▼ 295.1% | -84.38M▼ 32.9% | -41.66M▲ 50.6% | -31.54M▲ 24.3% | -35.13M▼ 11.4% | -78.26M▼ 122.8% | -84.74M▲ 0% |
Net Margin % | 42.68% | -218.55% | -238.1% | -947.9% | -1563.1% | -230.78% | -1639.5% | -7965.76% | -132642.37% | -143627.12% |
Net Income Growth % | 172.06% | -437.43% | 59.87% | -295.08% | -32.88% | 50.63% | 24.28% | -11.37% | -122.78% | -216.06% |
Net Income (Continuing) | 11.87M | -35.27M | -16.27M | -64.38M | -84.35M | -41.66M | -31.54M | -35.13M | -78.26M | -84.74M |
Discontinued Operations | 0 | 0 | 198.21K | 884K | -27K | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 1822.74▲ 0% | -3317.28▼ 282.0% | -819.74▲ 75.3% | -2523.77▼ 207.9% | -2330.66▲ 7.7% | -1062.65▲ 54.4% | -113.58▲ 89.3% | -3.26▲ 97.1% | -5.84▼ 79.1% | -4.21▲ 0% |
EPS Growth % | 8411.63% | -281.99% | 75.29% | -207.87% | 7.65% | 54.41% | 89.31% | 97.13% | -79.14% | -124.06% |
EPS (Basic) | 1856.88 | -3317.28 | -819.74 | -2523.77 | -2330.66 | -1062.65 | -113.58 | -4.32 | -5.84 | - |
Diluted Shares Outstanding | 6.51K | 12.07K | 19.85K | 25.51K | 36.19K | 39.2K | 277.73K | 10.78M | 13.4M | 20.11M |
Basic Shares Outstanding | 6.39K | 12.07K | 19.85K | 25.51K | 36.19K | 39.2K | 277.73K | 8.13M | 13.4M | 20.11M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
AVTX Balance Sheet
Avalo Therapeutics, Inc. (AVTX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 10.99M | 21.93M | 17.72M | 26M | 61.84M | 16.42M | 8.39M | 138.89M | 105.29M | 88.83M |
Cash & Short-Term Investments | 2.47M | 10.65M | 11.24M | 18.92M | 54.59M | 13.17M | 7.42M | 134.55M | 98.34M | 81.99M |
Cash Only | 2.47M | 10.65M | 3.61M | 18.92M | 54.59M | 13.17M | 7.42M | 134.55M | 15.86M | 24.99M |
Short-Term Investments | 0 | 0 | 7.63M | 0 | 0 | 0 | 0 | 0 | 82.48M | 57.01M |
Accounts Receivable | 2.94M | 6.08M | 5.24M | 4.38M | 4.8M | 1.92M | 136K | 611K | 0 | 0 |
Days Sales Outstanding | 38.52 | 121.18 | 283.45 | 238.92 | 324.5 | 38.8 | 25.8 | 505.7 | - | - |
Inventory | 382.15K | 1.11M | 21.33K | 3K | 38K | 20K | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | 219.44 | 54.22 | -13.75 | 3.65 | 9.3 | 2.13 | - | - | - | - |
Other Current Assets | 4.18M | 9.41M | 515.11K | 38K | 51K | 1.3M | 844K | 3.73M | 6.95M | 6.83M |
Total Non-Current Assets | 32.13M | 48.32M | 18.38M | 17.75M | 18.37M | 16.95M | 12.6M | 11.84M | 11.17M | 11.06M |
Property, Plant & Equipment | 44.61K | 586.51K | 1.45M | 1.61M | 2.69M | 2.41M | 1.97M | 1.21M | 460K | 375K |
Fixed Asset Turnover | 623.45x | 31.25x | 4.66x | 4.17x | 2.00x | 7.49x | 0.98x | 0.36x | 0.13x | 0.11x |
Goodwill | 14.29M | 16.41M | 14.41M | 14.41M | 14.41M | 14.41M | 10.5M | 10.5M | 10.5M | 10.5M |
Intangible Assets | 17.66M | 31.24M | 2.43M | 1.58M | 38K | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 131.35K | 81.72K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 131.35K | -91.24K | 101.94K | 149K | 1.23M | 131K | 131K | 131K | 210K | 183K |
Total Assets | 43.12M▲ 0% | 70.25M▲ 62.9% | 36.11M▼ 48.6% | 43.76M▲ 21.2% | 80.21M▲ 83.3% | 33.37M▼ 58.4% | 20.99M▼ 37.1% | 150.73M▲ 618.0% | 116.46M▼ 22.7% | 99.89M▲ 0% |
Asset Turnover | 0.64x | 0.26x | 0.19x | 0.15x | 0.07x | 0.54x | 0.09x | 0.00x | 0.00x | 0.00x |
Asset Growth % | 647.51% | 62.9% | -48.6% | 21.17% | 83.33% | -58.4% | -37.08% | 618.01% | -22.74% | -6.69% |
Total Current Liabilities | 11.41M | 26.22M | 12.16M | 15.22M | 19.89M | 22.11M | 4.62M | 6.96M | 12.94M | 11.6M |
Accounts Payable | 1.3M | 1.45M | 2.08M | 2.57M | 3.37M | 2.88M | 446K | 283K | 137K | 356K |
Days Payables Outstanding | 745.9 | 70.58 | -1.34K | 3.13K | 824.74 | 306.33 | 126.78 | -282.23 | - | 17.89K |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 5.93M | 0 | 0 | 0 | 328K |
Deferred Revenue (Current) | 0 | 2.03M | 0 | 0 | 0 | 88K | 0 | 0 | 0 | 0 |
Other Current Liabilities | 8.71M | 21.14M | 5.57M | 4.57M | 4.32M | 3.18M | 3.06M | 3.24M | 12.41M | 10.91M |
Current Ratio | 0.96x | 0.84x | 1.46x | 1.71x | 3.11x | 0.74x | 1.82x | 19.96x | 8.14x | 7.66x |
Quick Ratio | 0.93x | 0.79x | 1.46x | 1.71x | 3.11x | 0.74x | 1.82x | 19.96x | 8.14x | 7.66x |
Cash Conversion Cycle | -487.94 | 104.81 | 1.61K | -2.89K | -490.94 | -265.4 | - | - | - | - |
Total Non-Current Liabilities | 3.86M | 23.13M | 2.95M | 3.97M | 37.24M | 22.17M | 9.07M | 10.74M | 20.47M | 19.97M |
Long-Term Debt | 0 | 0 | 0 | 0 | 32.83M | 13.49M | 0 | 0 | 2M | 2M |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 35K | 349K |
Deferred Tax Liabilities | 7.14K | 69.24K | 85.98K | 90K | 113K | 141K | 155K | 270K | 434K | 1.48M |
Other Non-Current Liabilities | 3.85M | 23.06M | 2.87M | 3.88M | 4.3M | 8.54M | 8.92M | 10.47M | 18M | 17.52M |
Total Liabilities | 15.26M | 49.34M | 15.11M | 19.19M | 57.13M | 44.28M | 13.69M | 17.7M | 33.41M | 31.57M |
Total Debt | 0 | 15.38M | 155.81K | 426K | 33.32M | 19.95M | 537K | 568K | 2.43M | 2.33M |
Net Debt | -2.47M | 4.73M | -3.45M | -18.49M | -21.27M | 6.78M | -6.88M | -133.98M | -13.43M | -22.66M |
Debt / Equity | - | 0.74x | 0.01x | 0.02x | 1.44x | - | 0.07x | 0.00x | 0.03x | 0.03x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.03x |
Net Debt / EBITDA | -0.17x | - | - | - | - | - | - | - | - | 0.29x |
Interest Coverage | 578.36x | - | - | - | -34.35x | -8.98x | -6.86x | - | - | - |
Total Equity | 27.86M▲ 0% | 20.91M▼ 25.0% | 21M▲ 0.4% | 24.56M▲ 17.0% | 23.08M▼ 6.0% | -10.91M▼ 147.3% | 7.3M▲ 166.9% | 133.03M▲ 1721.4% | 83.05M▼ 37.6% | 68.32M▲ 0% |
Equity Growth % | 13358.75% | -24.95% | 0.42% | 16.99% | -6.03% | -147.29% | 166.92% | 1721.36% | -37.57% | 1120.99% |
Book Value per Share | 4278.14 | 1731.63 | 1057.76 | 962.80 | 637.78 | -278.43 | 26.30 | 12.34 | 6.20 | 3.40 |
Total Shareholders' Equity | 27.86M | 20.91M | 21M | 24.56M | 23.08M | -10.91M | 7.3M | 133.03M | 83.05M | 68.32M |
Common Stock | 2.69M | 40.8K | 44.38K | 75K | 9K | 0 | 1K | 10K | 18K | 25K |
Retained Earnings | -58.17M | -98.22M | -114.29M | -177.79M | -262.17M | -303.82M | -335.13M | -370.26M | -448.52M | -468.15M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 2.66M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 68K | -6K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AVTX Cash Flow Statement
Avalo Therapeutics, Inc. (AVTX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 12.52M | -3.13M | -19.13M | -40.54M | -70.89M | -26.75M | -30.68M | -49.06M | -51.46M | -59.69M |
Operating CF Margin % | 45.01% | -17.07% | -283.46% | -605.15% | -1313.3% | -148.2% | -1594.59% | -11123.81% | -87216.95% | - |
Operating CF Growth % | 185.91% | -124.99% | -511.69% | -111.87% | -74.87% | 62.27% | -14.69% | -59.9% | -4.9% | -93.68% |
Net Income | 11.87M | -40.05M | -16.07M | -63.5M | -84.38M | -41.66M | -31.54M | -35.13M | -78.26M | -84.74M |
Depreciation & Amortization | 425.48K | 4.55M | 3.88M | 1.84M | 1.66M | 166K | 158K | 169K | 344K | 226K |
Stock-Based Compensation | 1.16M | 2.43M | 2.53M | 6.79M | 8.17M | 7.55M | 3.48M | 5.85M | 13.62M | 11.24M |
Deferred Taxes | -832.63K | -16.75K | 16.74K | 197K | 22K | 28K | 14K | 114K | 165K | 169K |
Other Non-Cash Items | 366.23K | 21.22M | -7.47M | 18.57M | 794K | 7.22M | 6.46M | -15.35M | 8.83M | 11.85M |
Working Capital Changes | -466.75K | 8.73M | -2.03M | -4.44M | 2.84M | -60K | -9.24M | -4.71M | 3.84M | 1.56M |
Change in Receivables | -247.19K | -222.53K | 6.78M | -2.79M | 1.12M | 2.88M | 1.78M | -475K | 0 | 0 |
Change in Inventory | -202.62K | -311.2K | 532.95K | 18K | -35K | 18K | 20K | 0 | 0 | 0 |
Change in Payables | 96.06K | 82.45K | 1.02M | 99K | 796K | -487K | -2.44M | -163K | -146K | -325K |
Cash from Investing | -18.91M | 865.46K | -443K | 11.13M | -113K | -95K | -133K | 356K | -81.72M | -56.22M |
Capital Expenditures | -23.32K | -564.41K | -262.01K | -63K | -113K | -95K | -158K | 0 | 0 | 0 |
CapEx % of Revenue | 0.08% | 3.08% | 3.88% | 0.94% | 2.09% | 0.53% | 8.21% | - | - | 0% |
Acquisitions | -18.89M | 1.43M | 0 | 11.2M | 0 | 0 | 0 | 356K | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | -1K | -180.99K | 0 | 0 | 0 | 25K | 0 | 690K | 10.8M |
Cash from Financing | 3.74M | 10.4M | 12.56M | 44.78M | 106.76M | -14.7M | 25.04M | 175.85M | 14.59M | 15.99M |
Debt Issued (Net) | -2.37M | 0 | -256.14K | 0 | 32.9M | -14.81M | -21.24M | 0 | 0 | 0 |
Equity Issued (Net) | 6.34M | 3.86M | 12.68M | 44.45M | 71.93M | 107K | 46.22M | 115.63M | 15.1M | 17.27M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | -232.38K | 6.55M | 131.07K | 332K | 1.93M | 0 | 67K | 60.22M | -510K | -1.29M |
Net Change in Cash | -2.66M▲ 0% | 8.14M▲ 406.5% | -7.02M▼ 186.2% | 15.38M▲ 319.1% | 35.76M▲ 132.5% | -41.45M▼ 215.9% | -5.77M▲ 86.1% | 127.15M▲ 2303.2% | -118.59M▼ 193.3% | -100M▲ 0% |
Free Cash Flow | 12.5M▲ 0% | -3.69M▼ 129.5% | -19.4M▼ 425.3% | -40.6M▼ 109.3% | -71M▼ 74.9% | -26.85M▲ 62.2% | -30.84M▼ 14.9% | -49.06M▼ 59.1% | -51.46M▼ 4.9% | -59.69M▲ 0% |
FCF Margin % | 44.93% | -20.15% | -287.34% | -606.09% | -1315.39% | -148.72% | -1602.81% | -11123.81% | -87216.95% | -101172.88% |
FCF Growth % | 185.54% | -129.55% | -425.29% | -109.33% | -74.88% | 62.19% | -14.87% | -59.08% | -4.9% | -14.11% |
FCF per Share | 1918.91 | -305.82 | -977.20 | -1591.55 | -1961.95 | -684.81 | -111.04 | -4.55 | -3.84 | -2.97 |
FCF Conversion (FCF/Net Income) | 1.05x | 0.08x | 1.19x | 0.64x | 0.84x | 0.64x | 0.97x | 1.40x | 0.66x | 0.70x |
Interest Paid | 72.53K | 525K | 1.05M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 540K | 354K | 1.8M | 474K | 0 | 0 | 0 | 0 | 0 | 0 |
AVTX Key Ratios
Avalo Therapeutics, Inc. (AVTX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 84.58% | -164.26% | -76.71% | -278.77% | -354.19% | -684.77% | -431.87% | -50.06% | -72.43% | -97.55% |
Return on Invested Capital (ROIC) | 91.3% | -115.57% | -56.06% | - | -1562.67% | - | -4815.32% | - | -159.29% | -97.57% |
Gross Margin | 97.71% | 59.19% | 108.39% | 95.52% | 72.38% | 80.98% | 33.26% | 182.99% | 100% | 71.19% |
Net Margin | 42.68% | -218.55% | -238.1% | -947.9% | -1563.1% | -230.78% | -1639.5% | -7965.76% | -132642.37% | -143627.12% |
Debt / Equity | - | 0.74x | 0.01x | 0.02x | 1.44x | - | 0.07x | 0.00x | 0.03x | 0.03x |
Interest Coverage | 578.36x | - | - | - | -34.35x | -8.98x | -6.86x | - | - | - |
FCF Conversion | 1.05x | 0.08x | 1.19x | 0.64x | 0.84x | 0.64x | 0.97x | 1.40x | 0.66x | 0.70x |
Revenue Growth | 2312.24% | -34.11% | -63.17% | -0.76% | -19.42% | 234.4% | -89.34% | -77.08% | -86.62% | -86.62% |
Related:AVTX Dividend History·AVTX Revenue History·AVTX Price History·AVTX P/E History·AVTX Financial Ratios·AVTX Institutional Holders
AVTX SEC Filings & Documents
Avalo Therapeutics, Inc. (AVTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
AVTX Frequently Asked Questions
Avalo Therapeutics, Inc. (AVTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Avalo Therapeutics, Inc. (AVTX) reported $0.1M in revenue for fiscal year 2025. This represents a 29% decrease from $0.1M in 2012.
Avalo Therapeutics, Inc. (AVTX) saw revenue decline by 86.6% over the past year.
Avalo Therapeutics, Inc. (AVTX) reported a net loss of $84.7M for fiscal year 2025.
Dividend & Returns
Avalo Therapeutics, Inc. (AVTX) has a return on equity (ROE) of -72.4%. Negative ROE indicates the company is unprofitable.
Avalo Therapeutics, Inc. (AVTX) had negative free cash flow of $59.7M in fiscal year 2025, likely due to heavy capital investments.